About RECORNEA
RECORNEA is a company based in Udine (Italy) founded in 2019 by Kakanga Moses and Emiliano Lepore. RECORNEA has raised $162 thousand across 2 funding rounds from investors including European Union and Scientifica. RECORNEA offers products and services including GROSSO Reshaper and Glaucoma Filtering Device. RECORNEA operates in a competitive market with competitors including CorneaGen, Cellusion, EyeGate, Avedro and CorNeat Vision, among others.
- Headquarter Udine, Italy
- Founders Kakanga Moses, Emiliano Lepore
- SectorsHealthcare
- Email••••••••
- Website recornea.com
- Social LinkedIn
- Legal Name Recornea Srl
- Total Equity Funding$162K (USD)
in 2 rounds
- Latest Funding Round$162K (USD), Seed
Jul 2024
- InvestorsEuropean Union
& 1 more
Products & Services of RECORNEA
RECORNEA offers a comprehensive portfolio of products and services, including GROSSO Reshaper and Glaucoma Filtering Device.
Implant device for treating keratoconus to restore corneal shape and vision.
Minimally invasive device to reduce intraocular pressure in glaucoma patients.
Funding Insights of RECORNEA
RECORNEA has successfully raised a total of $162K across 2 strategic funding rounds. The most recent funding activity was a Seed round of $162 thousand completed in July 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $161,997
- Total Rounds 2
- Last Round Seed — $161,997
- First Round $619,283
(Nov 2019)
- Investors Count 2
All 2 funding rounds of RECORNEA with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2024 | $161,997 | Seed | – | Scientifica | – |
| Nov 2019 | $619,283 | Grant | – | – |
2 investors in total: 2 institutional.
Investors in RECORNEA
RECORNEA has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include European Union and Scientifica.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Scientifica is engaged in venture capital for technology startups. | – | scientifica.vc | Italy | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for RECORNEA
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of RECORNEA
2 people are tracked at RECORNEA (2 in leadership).
| Name | Role | Group |
|---|---|---|
Kakanga Moses | Co-Founder | Leadership |
Emiliano Lepore | Co-Founder & CEO | Leadership |
Complete people profiles for RECORNEA
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of RECORNEA
3 dated milestones of RECORNEA across 5 years, from founding to its latest funding, stage changes and deals.
- Founded RECORNEA is founded.
- Funding First funding round of $619K.
- Funding Latest funding round, Seed, of $162K.
Competitors of RECORNEA
RECORNEA operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as CorneaGen, Cellusion, EyeGate, Avedro and CorNeat Vision, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| corneagen.com | 2017 | Seattle, United States | $42M | 205 | Therapeutic devices for corneal transplants are developed by CorneaGen. | |
| cellusion.jp | 2015 | Minato, Japan | $29.71M | – | iPS cell-based technology for corneal endothelium regeneration is developed. | |
| eyegatepharma.com | 1998 | Waltham, United States | $44.47M | 12 | Therapeutics and drug delivery systems for eye diseases are developed. | |
| avedro.com | 2007 | Waltham, United States | $210.76M | 113 | Corneal collagen cross-linking technology is developed for ophthalmic applications. | |
| corneat.com | 2015 | – | $4M | – | Nanotechnology-based artificial corneal implants are developed for ophthalmic use. | |
| eye-yon.com | 2011 | Ness Ziona, Israel | $35.1M | – | Ophthalmic devices for corneal edema treatment are developed. | |
| nueyne.com | 2017 | Seoul, South Korea | – | – | Medical devices using electrical stimulation for health conditions are developed. | |
| biolatticetech.com | 2017 | Philadelphia, United States | – | – | Solutions for tissue repair and restoration are developed. |
Detailed competitors of RECORNEA
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of RECORNEA
The website of RECORNEA (recornea.com) receives about 1.8K visits a month.
- Monthly visits1.8K
▲ 71.9% vs previous month
Latest news on Recornea
Complete news archive for RECORNEA
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to RECORNEA
10 companies that operate in the same segment as RECORNEA (Ophthalmology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of a wide range of eye care products | 1945 | Fort Worth, Texas, United States | USD 171.61 M | USD 9.64 B | 25,600 | |
Genetic medicines are developed by 4DMT for transformative therapies. | 2013 | Emeryville, California, United States | USD 186.59 M | USD 85.21 M | 227 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 | |
Ophthalmic pharmaceuticals for diabetic macular edema are developed and commercialized. | 2003 | Alpharetta, Georgia, United States | USD 66.8 M | USD 80.75 M | 79 | |
AI-powered portable solutions for ophthalmic screening and diagnosis are developed. | 2009 | Bengaluru, Karnataka, India | USD 25.01 M | USD 4.85 M | 135 | |
Gene therapies for ocular and neurodegenerative diseases are developed. | 2015 | New York, New York, United States | – | USD 81.39 M | 381 | |
Small molecule therapeutics for ophthalmic disorders are developed. | 1987 | Watertown, United States | – | USD 31.37 M | 165 | |
Therapies for metabolic and orphan diseases are developed by Rezolute. | 2012 | Denver, Colorado, United States | – | – | 59 | |
Manufacturer of portable digital eye imaging devices and cloud-based healthcare platforms | 2010 | Bengaluru, Karnataka, India | USD 18.12 M | USD 4.78 M | 145 | |
Therapeutics for retinal diseases are developed by the company. | 2009 | Palo Alto, California, United States | USD 35.84 M | – | 109 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about RECORNEA
RECORNEA was founded in 2019.
RECORNEA is headquartered in Udine, Italy. It is registered at Udine, Friuli-venezia Giulia, Italy.
Emiliano Lepore is the current CEO of RECORNEA. They have also founded this company.
RECORNEA is a funded company, having raised a total of $162K across 2 funding rounds to date. The company's 1st funding round was a Grant of $619.28K, raised on Nov 2019.
RECORNEA was founded in 2019 in Udine, Italy, as a medical device company focused on corneal health. Therapeutic solutions are developed for conditions such as keratoconus and corneal transplants. Operations center on innovative implants, including the GROSSO Implant, a nitinol-based device designed to restore corneal curvature. Clinical outcomes are targeted for clarity and predictability in eye disease management.
RECORNEA offers GROSSO Reshaper and Glaucoma Filtering Device.
RECORNEA has 2 investors. Key investors include European Union, and Scientifica.
RECORNEA operates through Recornea Srl.